Change over period: —
NSE · GUJTHEM
GUJ.THEMIS.
-20.8% from the 52-week high · +58.3% above the low
Gujarat Themis Biosyn Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Mumbai, Maharashtra and currently employs 109 full-time employees. Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The firm is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The firm operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The firm is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.
The short version. Promoter holding was 59.33% in Sep 2026, down 11.53 points over 8 quarters.
1 · The price
How has the stock traded?
GUJ.THEMIS. trades 20.8% below its 52-week high and 58.3% above its 52-week low.
2 · The business
Is it growing?
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | |
|---|---|---|
| Revenue | 50 | 44 |
| Net profit | -14 | 11 |
| Net margin % | -27.7 | 25.3 |
| EPS (₹) | -1.06 | 1.02 |
4 · The owners
Who holds it, and are they adding?
Down 11.53 pts over 8 quarters.
Up 2.38 pts over 8 quarters.
Up 11.48 pts over 8 quarters.
+1 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.86 | 70.86 | 70.86 | 70.86 | 70.86 | 70.86 | 70.86 | 59.33 | -11.53 |
| FII | 1.42 | 1.91 | 2.51 | 2.95 | 1.96 | 1.8 | 1.77 | 3.8 | +2.38 |
| DII | 1.17 | 1.17 | 1.17 | 1.17 | 1.17 | 1.18 | 1.18 | 12.65 | +11.48 |
| Public | 26.54 | 26.05 | 25.45 | 25.01 | 26.0 | 26.16 | 26.19 | 24.22 | -2.32 |
Mutual fund holdings · Oct 2026
13 schemes hold this stock
12 the month before.
- quant Equity Savings Fund7.36% of NAV
- quant Manufacturing Fund5.45% of NAV
- SAMCO MULTI ASSET ALLOCATION FUND3.94% of NAV
- SAMCO ACTIVE MOMENTUM FUND1.27% of NAV
- Bank of India Value Fund1.22% of NAV
- Bank Of India Manufacturing and Infrastructure Fund1.02% of NAV
- Bank Of India SMALL CAP FUND0.96% of NAV
- Bank Of India Flexi Cap Fund0.84% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for GUJ.THEMIS. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about GUJ.THEMIS.
What is the GUJ.THEMIS. share price?
GUJ.THEMIS. (GUJTHEM) last closed at ₹352.70, down 1.81% on the day. Its 52-week range is ₹226.90 to ₹453.25.
What is the market cap of GUJ.THEMIS.?
GUJ.THEMIS. has a market capitalisation of about ₹4,243 crore.
How are GUJ.THEMIS.'s latest results?
Promoter holding was 59.33% in Sep 2026, down 11.53 points over 8 quarters.
Who owns GUJ.THEMIS.?
As of Sep 2026, shareholding was: Promoter 59.33%, FII 3.8%, DII 12.65%, Public 24.22%.
How many mutual funds hold GUJ.THEMIS.?
13 mutual fund schemes held GUJ.THEMIS. in October 2026. That compares with 12 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 04 Sep 2025 · Final Dividend - Rs. 0.67
- 09 Aug 2024 · Bonus issue 1:2
- 15 Jul 2024 · Final Dividend - Rs. 0.25
- 22 Feb 2024 · Interim Dividend - Rs. 0.75
- 10 Oct 2023 · Stock Split From Rs.5/- to Rs.1/-
- 01 Sep 2023 · Final Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.